September 08, 2026 06:14 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Eiffel Tower staff strike after female workers 'sidelined' during Hindu group visit | ‘When will character assassination of women stop?’ Kangana Ranaut amid Udhayanidhi-Trisha row | 11 arms instead of 10! Suvendu Adhikari apologises over Durga image in Bengal govt ad amid Bageshwar Baba row | ‘Meat is core to Shakta Hinduism’: PM Modi adviser hits back at Bageshwar Baba over non-veg ban appeal | ‘No one can dictate what Bengalis eat’: BJP’s blunt message amid Bageshwar Baba’s Durga Puja food row | Delhi hostel collapse: Owner detained after seven die in Satya Niketan tragedy | No Muslims, Aadhaar card and tilak mandatory: VHP lays down rules for Garba, Dandiya in Maharashtra | 'No non-veg near Durga Puja pandals': Bageshwar Baba's big Bengal appeal sparks controversy | 'Law will take its action': Vijay's zero tolerance on insulting women weeks after Udhayanidhi's arrest | Delhi Metro's big warning to content creators: Don't try this viral stunt or face action

Strides Arcolab signs agreement with Gilead Sciences

| | Jan 21, 2015, at 02:38 am
Bangalore/Kolkata, Jan 20 (IBNS): Strides Arcolab Limited (Strides) on Tuesday announced that it has entered into a licensing agreement with Gilead Sciences, Inc. under which Gilead has extended non-exclusive rights to Strides to manufacture and distribute Tenofovir Alafenamide (TAF), both as a single agent product and in combination with other drugs.
The license being granted to Strides extends to 112 countries, which together account for more than 30 million people living with HIV.
 
As part of the licensing agreement, pending U.S. Food and Drug Administration (US FDA) approval of the Gilead product, Strides will receive a technology transfer from Gilead, enabling Strides to manufacture low-cost versions of TAF for developing countries.
 
TAF is a novel nucleotide reverse transcriptase inhibitor that has demonstrated high antiviral efficacy at a dose 10 times lower than Gilead’s Viread (tenofovir disoproxil fumarate), as well as an improved renal and bone safety profile.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.